Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07418749RecruitingPhase 3
Testing a new drug for advanced cervical cancer after standard treatments
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
Guangzhou, GuangdongAges 18 years+ - NCT07424664RecruitingPhase 2
Combination targeted drug and immunotherapy for recurrent gynecologic cancers
This trial tests a combination of two new drugs—becotatug vedotin (targeted therapy) and zimberelimab (immunotherapy)—in people with recurrent or metastatic cervical, vulvar, or vaginal cancer. The goal is to see if this combination works after standard treatments like platinum chemotherapy and immunotherapy have been tried.
Wuhan, HubeiAges 18–75 - NCT07472153RecruitingPhase 2/Phase 3
Immunotherapy plus chemo for advanced cervical cancer
This trial tests adding immunotherapy drugs (PD-1 or PD-L1 inhibitors) to standard chemotherapy, with or without bevacizumab, for people with cervical cancer that has spread, persisted, or come back after treatment. The goal is to see which combination works better.
Minsk, LesnoyAges 18–75 - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT07532018RecruitingPhase 1
DXP-106 Treatment for Advanced Solid Tumors
This early-stage trial tests a new drug called DXP-106 in patients with advanced cancers (like lung, pancreatic, or breast cancer) that have stopped responding to standard treatments. The study aims to find the right dose and see if this drug can help slow or shrink these tumors.
Harbin, HeilongjiangAges 18–75 - NCT07552233Recruiting
NK Cell Therapy for Recurrent Brain Tumors
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07563972RecruitingPhase 1
Immune Cell Injection for Advanced Solid Tumors
This trial tests a new treatment where immune cells (called macrophage exosomes) are injected directly into your tumor to help your body fight the cancer. It's designed for advanced cancers that have not responded to standard treatments.
Chengdu, SichuanAges 18–65 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07636200Recruiting
Managing Fear and Worry in Advanced Cancer
This study tests a new approach to help people with advanced cancer who feel significant fear about their cancer getting worse or coming back. The program uses writing and therapeutic techniques to help reduce this fear and related stress.
Aurora, ColoradoAges 18 years+ - NCT07651124Recruiting
Testing a cell therapy for recurrent ovarian cancer
This trial tests a treatment where doctors take immune cells from your tumor, grow more of them in the lab, and put them back into your body to fight the cancer. This approach, called TIL therapy, aims to strengthen your own immune system to target ovarian cancer that has come back.
Gyeonggi-do, Bundang-guAges 20 years+ - NCT07661641RecruitingPhase 1
Study of new radioactive treatments for GRPR-positive tumors
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
Melbourne N., VictoriaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06606990RecruitingPhase 1
Testing the drug CX-5461 for advanced solid tumors
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
Bethesda, MarylandAges 18 years+ - NCT06980038RecruitingPhase 2
Testing two immunotherapy drugs before surgery for advanced head and neck cancer
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Irvine, CaliforniaAges 18 years+ - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT04329494RecruitingPhase 1
Study of targeted drug delivery into the abdomen using PIPAC
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Duarte, CaliforniaAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT05759923RecruitingPhase 1
Study of OATD-02 for hard-to-treat solid tumors
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Bydgoszcz, Kuyavian-Pomeranian VoivodeshipAges 18 years+ - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT04541082RecruitingPhase 1
Oral ONC206 for recurrent brain and spinal tumors
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Bethesda, MarylandAges 18 years+ - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,355 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.